Clinical Trials
7 trialsNCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04398927 2021-02-04
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Sun Yat-sen University
Phase 2 Withdrawn
NCT04400851 2020-09-03
Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors
Sun Yat-sen University
Phase 1 Unknown
NCT04202601 2019-12-19
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
Peking University
Phase 1/2 Unknown